Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LOTEMAX

« Back to Dashboard

Lotemax is a drug marketed by Bausch And Lomb Inc, Bausch And Lomb, and Pharmos. and is included in four NDAs. It is available from two suppliers. There are four patents protecting this drug.

The generic ingredient in LOTEMAX is loteprednol etabonate. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

Summary for Tradename: LOTEMAX

Patents:4
Applicants:3
NDAs:4
Suppliers: see list2

Pharmacology for Tradename: LOTEMAX

Clinical Trials for: LOTEMAX

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Status: Active, not recruiting Condition: Dry Eyes

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Status: Active, not recruiting Condition: Meibomian Gland Dysfunction; Posterior Blepharitis

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Status: Completed Condition: Conjunctivitis

Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca
Status: Completed Condition: Keratoconjunctivitis Sicca

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Status: Completed Condition: Inflammation; Pain; Cataract

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Status: Completed Condition: Dry Eye

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Status: Active, not recruiting Condition: Pseudophakia; Inflammation

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Status: Completed Condition: Allergic Conjunctivitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583Mar 9, 1998RXYes5,540,930*PED<disabled>Y<disabled>
Bausch And Lomb Inc
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC202872Sep 28, 2012RXYes5,800,807<disabled>Y<disabled>
Pharmos
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020841Mar 9, 1998DISCNNo5,540,930<disabled><disabled>
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583Mar 9, 1998RXYes5,747,061*PED<disabled>Y<disabled>
Bausch And Lomb
LOTEMAX
loteprednol etabonate
OINTMENT;OPHTHALMIC200738Apr 15, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc